[시장보고서]폐암 진단약 시장, 진단 검사 유형 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

폐암 진단약 시장, 진단 검사 유형 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Lung Cancer Diagnostics Market, Diagnostic Test Type - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1606343

리서치사 : Transparency Market Research

발행일 : 2024년 10월

페이지 정보 : 영문 228 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,056,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,227,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 16,398,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

폐암 진단약 시장 - 조사 범위

TMR의 조사 리포트 '세계의 폐암 진단약 시장'은 2024-2034년의 예측 기간에 시장의 지표에 관한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사하고 있습니다. 2024년을 기준년, 2034년을 예측년으로 2018-2034년의 세계 폐암 진단약 시장의 매출과 예측을 제공하고 있습니다. 또한 2024-2034년의 세계 폐암 진단약 시장의 연평균 성장률(CAGR %)도 게재하고 있습니다.

본 리포트는 광범위한 조사를 거쳐 작성되고 있습니다. 1차 조사에서는 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 메이커에 대한 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 애뉴얼 리포트, 프레스 릴리스, 관련 자료 등을 참조하여 폐암 진단약 시장을 추측했습니다.

시장 스냅숏
2023년 시장 규모	151억 달러
2034년 시장 규모	348억 달러
CAGR	7.9%

본 리포트에서는 세계의 폐암 진단약 시장의 경쟁 구도에 대해 심층 분석하고 있습니다. 세계의 폐암 진단약 시장에서 사업을 운영하는 주요 기업이 식별되고, 각 기업이 다양한 속성으로 프로파일링되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT 등이 본 리포트에서 소개하고 있는 세계의 폐암 진단약 시장에서 기업의 속성입니다.

산업계에서 최근 기술 진보
폐암 진단 툴로서의 액체생검의 출현에 관한 인사이트
가격 동향
주요 지역/국에서 규제 상황
Porter's Five Forces 분석
PESTEL 분석
밸류체인 분석
신규 참여자를 위한 시장 개척 전략
최종사용자의 주요 구입 지표
주요 업계 이벤트(파트너십, 협업, 제품 승인, 합병과 인수, 자금조달과 투자)
경쟁이 제공하는 제품의 벤치마킹

제6장 세계 시장 분석과 예측 : 진단 테스트 유형별

서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 진단 테스트 유형별, 2020-2034년
- 생검
  - 침생검
  - 경기관지 생검
  - 흉강경하 생검
  - 액체생검
    - 순환종양세포(CTC)
    - 순환 종양 DNA
    - 유리 RNA(cfRNA)
    - 엑소좀
    - 프로테옴 해석
  - 기타
- 영상 검사
  - 자기공명영상(MRI)
  - 컴퓨터 단층촬영(CT) 스캔
  - 흉부 초음파 검사
  - 양전자 방출 단층촬영(PET)
  - 기타 영상 검사
- 분자 검사
- 기타
진단 테스트 유형별 시장의 매력

제7장 세계 시장 분석과 예측 : 제품 유형별

서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 제품 유형별, 2020-2034년
- 기기
- 소모품
제품 유형별 시장의 매력

제8장 세계 시장 분석과 예측 : 암 유형별

서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 암 유형별, 2020-2034년
- 비소세포 폐암(NSCLC)
- 소세포 폐암(SCLC)
암 유형별 시장의 매력

제9장 세계 시장 분석과 예측 : 최종사용자별

서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 최종사용자별, 2020-2034년
- 병원
- 클리닉
- 진단·영상 진단 센터
- 암조사기관
최종사용자별 시장의 매력

제10장 세계 시장 분석과 예측 : 지역별

주요 조사 결과
시장 금액 예측 : 지역별
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
지역별 시장의 매력

제11장 북미의 시장 분석과 예측

미국
캐나다

제12장 유럽의 시장 분석과 예측

독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역

제13장 아시아태평양의 시장 분석과 예측

중국
일본
인도
호주와 뉴질랜드
기타 아시아태평양

제14장 라틴아메리카의 시장 분석과 예측

브라질
멕시코
기타 라틴아메리카 지역

제15장 중동 및 아프리카의 시장 분석과 예측

GCC 국가
남아프리카공화국
기타 중동 및 아프리카

제16장 경쟁 구도

시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
시장 점유율 분석 기업별(2023년)
기업 개요
- Abbott
- Siemens Healthcare
- GE Healthcare
- Amoy Diagnostics Co.
- Boditech Med, Inc.
- Danaher
- F. Hoffmann-La Roche
- INOVIQ
- MedGenome
- Quest Diagnostics Incorporated
- DiaSorin S.p.A.
- Oncocyte Corporation
- QIAGEN
- Thermo Fisher Scientific, Inc.
- NanoString Technologies
- Biodesix
- Other Prominent Players

KSA

영문 목차

영문목차

Lung Cancer Diagnostics Market - Scope of Report

TMR's report on the global lung cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global lung cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung cancer diagnostics market.

Market Snapshot
Market Value in 2023	US$ 15.1 Bn
Market Value in 2034	US$ 34.8 Bn
CAGR	7.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lung cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer diagnostics market.

The report delves into the competitive landscape of the global lung cancer diagnostics market. Key players operating in the global lung cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lung cancer diagnostics market profiled in this report.

Key Questions Answered in Global lung cancer diagnostics Market Report:

What is the sales/revenue generated by lung cancer diagnostics across all regions during the forecast period?
What are the opportunities in the global lung cancer diagnostics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Lung Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global lung cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lung cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lung cancer diagnostics market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Lung Cancer Diagnostics Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2020-2034
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. Recent Technological Advancements in Lung Cancer Diagnostics Industry
5.2. Insights on Emergence of Liquid Biopsy as a Lung Cancer Diagnostic Tool
5.3. Lung Cancer Diagnostics Pricing Trends
5.4. Regulatory Landscape across Key Regions / Countries
5.5. PORTER's Five Forces Analysis
5.6. PESTEL Analysis
5.7. Value Chain Analysis
5.8. Go-To Market Strategy for New Entrants
5.9. Key Purchase Metrics for End-users
5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
5.11. Benchmarking of the Products Offered by the Competitors

6. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Diagnostic Test Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Diagnostic Test Type, 2020-2034
- 6.3.1. Biopsy
  - 6.3.1.1. Needle biopsy
  - 6.3.1.2. Transbronchial biopsy
  - 6.3.1.3. Thoracoscopic biopsy
  - 6.3.1.4. Liquid Biopsy
    - 6.3.1.4.1. Circulating Tumor Cells (CTCs)
    - 6.3.1.4.2. Circulating Tumor DNA
    - 6.3.1.4.3. Cell-Free RNA (cfRNA)
    - 6.3.1.4.4. Exosomes
    - 6.3.1.4.5. Proteomic Analysis
  - 6.3.1.5. Others
- 6.3.2. Imaging Tests
  - 6.3.2.1. Magnetic Resonance Imaging (MRI)
  - 6.3.2.2. Computed Tomography (CT) Scan
  - 6.3.2.3. Chest Ultrasound
  - 6.3.2.4. Positron Emission Tomography (PET)
  - 6.3.2.5. Other Imaging Tests
- 6.3.3. Molecular Testing
- 6.3.4. Others
6.4. Market Attractiveness By Diagnostic Test Type

7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Product Type

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product Type, 2020-2034
- 7.3.1. Instruments
- 7.3.2. Consumables
7.4. Market Attractiveness By Product Type

8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Cancer Type

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Cancer Type, 2020-2034
- 8.3.1. Non-small cell lung cancer (NSCLC)
- 8.3.2. Small cell lung cancer (SCLC)
8.4. Market Attractiveness By Cancer Type

9. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By End-user

9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020-2034
- 9.3.1. Hospitals
- 9.3.2. Clinics
- 9.3.3. Diagnostic & Imaging Centers
- 9.3.4. Cancer Research Institutes
9.4. Market Attractiveness By End-user

10. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region

10.1. Key Findings
10.2. Market Value Forecast By Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region

11. North America Lung Cancer Diagnostics Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
- 11.2.1. Biopsy
  - 11.2.1.1. Needle biopsy
  - 11.2.1.2. Transbronchial biopsy
  - 11.2.1.3. Thoracoscopic biopsy
  - 11.2.1.4. Liquid Biopsy
    - 11.2.1.4.1. Circulating Tumor Cells (CTCs)
    - 11.2.1.4.2. Circulating Tumor DNA
    - 11.2.1.4.3. Cell-Free RNA (cfRNA)
    - 11.2.1.4.4. Exosomes
    - 11.2.1.4.5. Proteomic Analysis
  - 11.2.1.5. Others
- 11.2.2. Imaging Tests
  - 11.2.2.1. Magnetic Resonance Imaging (MRI)
  - 11.2.2.2. Computed Tomography (CT) Scan
  - 11.2.2.3. Chest Ultrasound
  - 11.2.2.4. Positron Emission Tomography (PET)
  - 11.2.2.5. Other Imaging Tests
- 11.2.3. Molecular Testing
- 11.2.4. Others
11.3. Market Value Forecast By Product Type, 2020-2034
- 11.3.1. Instruments
- 11.3.2. Consumables
11.4. Market Value Forecast By Cancer Type, 2020-2034
- 11.4.1. Non-small cell lung cancer (NSCLC)
- 11.4.2. Small cell lung cancer (SCLC)
11.5. Market Value Forecast By End-user, 2020-2034
- 11.5.1. Hospitals
- 11.5.2. Clinics
- 11.5.3. Diagnostic & Imaging Centers
- 11.5.4. Cancer Research Institutes
11.6. Market Value Forecast By Country, 2020-2034
- 11.6.1. U.S.
- 11.6.2. Canada
11.7. Market Attractiveness Analysis
- 11.7.1. By Diagnostic Test Type
- 11.7.2. By Product Type
- 11.7.3. By Cancer Type
- 11.7.4. By End-user
- 11.7.5. By Country

12. Europe Lung Cancer Diagnostics Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
- 12.2.1. Biopsy
  - 12.2.1.1. Needle biopsy
  - 12.2.1.2. Transbronchial biopsy
  - 12.2.1.3. Thoracoscopic biopsy
  - 12.2.1.4. Liquid Biopsy
    - 12.2.1.4.1. Circulating Tumor Cells (CTCs)
    - 12.2.1.4.2. Circulating Tumor DNA
    - 12.2.1.4.3. Cell-Free RNA (cfRNA)
    - 12.2.1.4.4. Exosomes
    - 12.2.1.4.5. Proteomic Analysis
  - 12.2.1.5. Others
- 12.2.2. Imaging Tests
  - 12.2.2.1. Magnetic Resonance Imaging (MRI)
  - 12.2.2.2. Computed Tomography (CT) Scan
  - 12.2.2.3. Chest Ultrasound
  - 12.2.2.4. Positron Emission Tomography (PET)
  - 12.2.2.5. Other Imaging Tests
- 12.2.3. Molecular Testing
- 12.2.4. Others
12.3. Market Value Forecast By Product Type, 2020-2034
- 12.3.1. Instruments
- 12.3.2. Consumables
12.4. Market Value Forecast By Cancer Type, 2020-2034
- 12.4.1. Non-small cell lung cancer (NSCLC)
- 12.4.2. Small cell lung cancer (SCLC)
12.5. Market Value Forecast By End-user, 2020-2034
- 12.5.1. Hospitals
- 12.5.2. Clinics
- 12.5.3. Diagnostic & Imaging Centers
- 12.5.4. Cancer Research Institutes
12.6. Market Value Forecast By Country / Sub-region, 2020-2034
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Spain
- 12.6.5. Italy
- 12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
- 12.7.1. By Diagnostic Test Type
- 12.7.2. By Product Type
- 12.7.3. By Cancer Type
- 12.7.4. By End-user
- 12.7.5. By Country / Sub-region

13. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
- 13.2.1. Biopsy
  - 13.2.1.1. Needle biopsy
  - 13.2.1.2. Transbronchial biopsy
  - 13.2.1.3. Thoracoscopic biopsy
  - 13.2.1.4. Liquid Biopsy
    - 13.2.1.4.1. Circulating Tumor Cells (CTCs)
    - 13.2.1.4.2. Circulating Tumor DNA
    - 13.2.1.4.3. Cell-Free RNA (cfRNA)
    - 13.2.1.4.4. Exosomes
    - 13.2.1.4.5. Proteomic Analysis
  - 13.2.1.5. Others
- 13.2.2. Imaging Tests
  - 13.2.2.1. Magnetic Resonance Imaging (MRI)
  - 13.2.2.2. Computed Tomography (CT) Scan
  - 13.2.2.3. Chest Ultrasound
  - 13.2.2.4. Positron Emission Tomography (PET)
  - 13.2.2.5. Other Imaging Tests
- 13.2.3. Molecular Testing
- 13.2.4. Others
13.3. Market Value Forecast By Product Type, 2020-2034
- 13.3.1. Instruments
- 13.3.2. Consumables
13.4. Market Value Forecast By Cancer Type, 2020-2034
- 13.4.1. Non-small cell lung cancer (NSCLC)
- 13.4.2. Small cell lung cancer (SCLC)
13.5. Market Value Forecast By End-user, 2020-2034
- 13.5.1. Hospitals
- 13.5.2. Clinics
- 13.5.3. Diagnostic & Imaging Centers
- 13.5.4. Cancer Research Institutes
13.6. Market Value Forecast By Country / Sub-region, 2020-2034
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
- 13.7.1. By Diagnostic Test Type
- 13.7.2. By Product Type
- 13.7.3. By Cancer Type
- 13.7.4. By End-user
- 13.7.5. By Country / Sub-region

14. Latin America Lung Cancer Diagnostics Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
- 14.2.1. Biopsy
  - 14.2.1.1. Needle biopsy
  - 14.2.1.2. Transbronchial biopsy
  - 14.2.1.3. Thoracoscopic biopsy
  - 14.2.1.4. Liquid Biopsy
    - 14.2.1.4.1. Circulating Tumor Cells (CTCs)
    - 14.2.1.4.2. Circulating Tumor DNA
    - 14.2.1.4.3. Cell-Free RNA (cfRNA)
    - 14.2.1.4.4. Exosomes
    - 14.2.1.4.5. Proteomic Analysis
  - 14.2.1.5. Others
- 14.2.2. Imaging Tests
  - 14.2.2.1. Magnetic Resonance Imaging (MRI)
  - 14.2.2.2. Computed Tomography (CT) Scan
  - 14.2.2.3. Chest Ultrasound
  - 14.2.2.4. Positron Emission Tomography (PET)
  - 14.2.2.5. Other Imaging Tests
- 14.2.3. Molecular Testing
- 14.2.4. Others
14.3. Market Value Forecast By Product Type, 2020-2034
- 14.3.1. Instruments
- 14.3.2. Consumables
14.4. Market Value Forecast By Cancer Type, 2020-2034
- 14.4.1. Non-small cell lung cancer (NSCLC)
- 14.4.2. Small cell lung cancer (SCLC)
14.5. Market Value Forecast By End-user, 2020-2034
- 14.5.1. Hospitals
- 14.5.2. Clinics
- 14.5.3. Diagnostic & Imaging Centers
- 14.5.4. Cancer Research Institutes
14.6. Market Value Forecast By Country / Sub-region, 2020-2034
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
- 14.7.1. By Diagnostic Test Type
- 14.7.2. By Product Type
- 14.7.3. By Cancer Type
- 14.7.4. By End-user
- 14.7.5. By Country / Sub-region

15. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
- 15.2.1. Biopsy
  - 15.2.1.1. Needle biopsy
  - 15.2.1.2. Transbronchial biopsy
  - 15.2.1.3. Thoracoscopic biopsy
  - 15.2.1.4. Liquid Biopsy
    - 15.2.1.4.1. Circulating Tumor Cells (CTCs)
    - 15.2.1.4.2. Circulating Tumor DNA
    - 15.2.1.4.3. Cell-Free RNA (cfRNA)
    - 15.2.1.4.4. Exosomes
    - 15.2.1.4.5. Proteomic Analysis
  - 15.2.1.5. Others
- 15.2.2. Imaging Tests
  - 15.2.2.1. Magnetic Resonance Imaging (MRI)
  - 15.2.2.2. Computed Tomography (CT) Scan
  - 15.2.2.3. Chest Ultrasound
  - 15.2.2.4. Positron Emission Tomography (PET)
  - 15.2.2.5. Other Imaging Tests
- 15.2.3. Molecular Testing
- 15.2.4. Others
15.3. Market Value Forecast By Product Type, 2020-2034
- 15.3.1. Instruments
- 15.3.2. Consumables
15.4. Market Value Forecast By Cancer Type, 2020-2034
- 15.4.1. Non-small cell lung cancer (NSCLC)
- 15.4.2. Small cell lung cancer (SCLC)
15.5. Market Value Forecast By End-user, 2020-2034
- 15.5.1. Hospitals
- 15.5.2. Clinics
- 15.5.3. Diagnostic & Imaging Centers
- 15.5.4. Cancer Research Institutes
15.6. Market Value Forecast By Country / Sub-region, 2020-2034
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
- 15.7.1. By Diagnostic Test Type
- 15.7.2. By Product Type
- 15.7.3. By Cancer Type
- 15.7.4. By End-user
- 15.7.5. By Country / Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2023)
16.3. Company Profiles
- 16.3.1. Abbott
  - 16.3.1.1. Company Overview
  - 16.3.1.2. Financial Overview
  - 16.3.1.3. Product Portfolio
  - 16.3.1.4. Business Strategies
  - 16.3.1.5. Recent Developments
- 16.3.2. Siemens Healthcare
  - 16.3.2.1. Company Overview
  - 16.3.2.2. Financial Overview
  - 16.3.2.3. Product Portfolio
  - 16.3.2.4. Business Strategies
  - 16.3.2.5. Recent Developments
- 16.3.3. GE Healthcare
  - 16.3.3.1. Company Overview
  - 16.3.3.2. Financial Overview
  - 16.3.3.3. Product Portfolio
  - 16.3.3.4. Business Strategies
  - 16.3.3.5. Recent Developments
- 16.3.4. Amoy Diagnostics Co.
  - 16.3.4.1. Company Overview
  - 16.3.4.2. Financial Overview
  - 16.3.4.3. Product Portfolio
  - 16.3.4.4. Business Strategies
  - 16.3.4.5. Recent Developments
- 16.3.5. Boditech Med, Inc.
  - 16.3.5.1. Company Overview
  - 16.3.5.2. Financial Overview
  - 16.3.5.3. Product Portfolio
  - 16.3.5.4. Business Strategies
  - 16.3.5.5. Recent Developments
- 16.3.6. Danaher
  - 16.3.6.1. Company Overview
  - 16.3.6.2. Financial Overview
  - 16.3.6.3. Product Portfolio
  - 16.3.6.4. Business Strategies
  - 16.3.6.5. Recent Developments
- 16.3.7. F. Hoffmann-La Roche
  - 16.3.7.1. Company Overview
  - 16.3.7.2. Financial Overview
  - 16.3.7.3. Product Portfolio
  - 16.3.7.4. Business Strategies
  - 16.3.7.5. Recent Developments
- 16.3.8. INOVIQ
  - 16.3.8.1. Company Overview
  - 16.3.8.2. Financial Overview
  - 16.3.8.3. Product Portfolio
  - 16.3.8.4. Business Strategies
  - 16.3.8.5. Recent Developments
- 16.3.9. MedGenome
  - 16.3.9.1. Company Overview
  - 16.3.9.2. Financial Overview
  - 16.3.9.3. Product Portfolio
  - 16.3.9.4. Business Strategies
  - 16.3.9.5. Recent Developments
- 16.3.10. Quest Diagnostics Incorporated
  - 16.3.10.1. Company Overview
  - 16.3.10.2. Financial Overview
  - 16.3.10.3. Product Portfolio
  - 16.3.10.4. Business Strategies
  - 16.3.10.5. Recent Developments
- 16.3.11. DiaSorin S.p.A.
  - 16.3.11.1. Company Overview
  - 16.3.11.2. Financial Overview
  - 16.3.11.3. Product Portfolio
  - 16.3.11.4. Business Strategies
  - 16.3.11.5. Recent Developments
- 16.3.12. Oncocyte Corporation
  - 16.3.12.1. Company Overview
  - 16.3.12.2. Financial Overview
  - 16.3.12.3. Product Portfolio
  - 16.3.12.4. Business Strategies
  - 16.3.12.5. Recent Developments
- 16.3.13. QIAGEN
  - 16.3.13.1. Company Overview
  - 16.3.13.2. Financial Overview
  - 16.3.13.3. Product Portfolio
  - 16.3.13.4. Business Strategies
  - 16.3.13.5. Recent Developments
- 16.3.14. Thermo Fisher Scientific, Inc.
  - 16.3.14.1. Company Overview
  - 16.3.14.2. Financial Overview
  - 16.3.14.3. Product Portfolio
  - 16.3.14.4. Business Strategies
  - 16.3.14.5. Recent Developments
- 16.3.15. NanoString Technologies
  - 16.3.15.1. Company Overview
  - 16.3.15.2. Financial Overview
  - 16.3.15.3. Product Portfolio
  - 16.3.15.4. Business Strategies
  - 16.3.15.5. Recent Developments
- 16.3.16. Biodesix
  - 16.3.16.1. Company Overview
  - 16.3.16.2. Financial Overview
  - 16.3.16.3. Product Portfolio
  - 16.3.16.4. Business Strategies
  - 16.3.16.5. Recent Developments
- 16.3.17. Other Prominent Players
  - 16.3.17.1. Company Overview
  - 16.3.17.2. Financial Overview
  - 16.3.17.3. Product Portfolio
  - 16.3.17.4. Business Strategies
  - 16.3.17.5. Recent Developments